Drugs / INTERCEPT Fibrinogen Complex
INTERCEPT Fibrinogen Complex
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05711524 | Apr 2023 → Oct 2024 | coagulation protein disease, hemorrhagic disease | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT06764927 Comparator | Jan → Mar 2026 | — | Ezeldeen Abuelkasem | Withdrawn | No outcome recorded |
| Phase 4 | NCT07265843 Comparator | Jan 2026 → Mar 2028 expected | — | Trauma Hemostatis and Oxygenation Research (THOR) Network | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INTERCEPT Fibrinogen Complex | “Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) can be kept thawed” PMID 39334317 ↗ Sep 2024 |
| Known as | IFC | “Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) can be kept thawed” PMID 39334317 ↗ Sep 20242“Investigational Cryoprecipitate Intercept Fibrinogen Complex (IFC)” NCT06764927 ↗ “Intercept Fibrinogen Complex (IFC)” NCT07265843 ↗ |
| Known as | Pathogen Reduced Cryoprecipitated Fibrinogen Complex | “Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) can be kept thawed” PMID 39334317 ↗ Sep 2024 |
| Action | Restore | “earlier correction of acquired hypofibrinogenemia with IFC in hemorrhaging cardiac surgery patients reduces the total number of perioperatively transfused allogeneic blood products” PMID 39334317 ↗ Sep 2024 |
| Modality | Protein / enzyme biologic | “Biological: Pathogen-Reduced Cryoprecipitate” NCT05711524 ↗ |